Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1

@inproceedings{Ponte2016MirvetuximabS,
  title={Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1},
  author={Jose F. Ponte and Olga Ab and Leanne Lanieri and Jenny Hyunjung Lee and Jennifer A Coccia and Laura M. Bartle and Marian Themeles and Yinghui Zhou and Jan Pinkas and Rodrigo Ruiz-Soto},
  booktitle={Neoplasia},
  year={2016}
}
Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this receptor as a candidate target for the development of novel therapeutics to treat this disease. Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that targets FRα for tumor-directed delivery of the maytansinoid DM4, a potent agent that induces mitotic arrest by suppressing microtubule dynamics. Here, combinations of IMGN853 with approved therapeutics… CONTINUE READING
7 Extracted Citations
57 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 57 references

Mirvetuximab soravtansine. Folate receptor alpha (FRa)-targeting antibody drug conjugate, treatment of epithelial ovarian cancer

  • CC Gunderson, KM Moore
  • Drugs Future
  • 2016
1 Excerpt

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors

  • PeethambaramPP, LC Hartmann, +7 authors V Teslenko
  • Invest New Drugs
  • 2015
1 Excerpt

Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer

  • G Jansen, GJ Peters
  • Pteridines
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…